← Leaderboards
Steven Schenker
University Of Texas Hlth Sci Ctr San Ant
$1,507,476
Attributed
$1,507,476
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,507,476 · 7
By mechanism
M01$1,507,476 · 7
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Lynette C Daws$13,518,910
- John G Kuhn$1,375,397
- Alan Frazer$9,968,319
- Arlan G. Richardson$23,573,173
- David Murray$759,954
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationLiver Disorder ChemotherapyNutrition Related TagPharmacokineticsLiver DisorderDrug Screening /EvaluationClinical Trial Phase IDosageDiet TherapyAcetaminophenAntiadrenergic AgentsClearance RateInflammationLipid MetabolismAlcoholic Liver CirrhosisFastingBlood ChemistryDrug MetabolismFibrosisGlutathioneBiopsyHepatotoxin
Grant awards (16)
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS$234,837
M01 · FY2002 · RR
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM &DISPOSITION$234,837
M01 · FY2002 · RR
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM &DISPOSITION$234,837
M01 · FY2002 · RR
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS$234,837
M01 · FY2002 · RR
PHARMACOKINETICS OF VASOMAX IN SUBJECTS WITH LIVER DIS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF VASOMAX IN SUBJECTS WITH LIVER DIS$0
M01 · FY2002 · RR
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM &DISPOSITION$234,837
M01 · FY2001 · RR
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS$234,837
M01 · FY2001 · RR
PHARMACOKINETICS OF VASOMAX IN SUBJECTS WITH LIVER DIS$0
M01 · FY2001 · RR
PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE$16,409
M01 · FY2000 · RR
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS$16,409
M01 · FY2000 · RR
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM &DISPOSITION$16,409
M01 · FY2000 · RR
PHARMACOKINETICS OF SCH39166 IN SUBJECTS W/ CHRONIC LIVER DISEASE$16,409
M01 · FY2000 · RR
BRL49653 IN PATIENTS WITH HEPATIC IMPAIRMENT$16,409
M01 · FY2000 · RR
IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE$16,409
M01 · FY2000 · RR
PHARMACOKINETICS OF VASOMAX IN SUBJECTS WITH LIVER DIS$0
M01 · FY2000 · RR